CompletedPhase 2NCT03126019
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Studying Tumor of hematopoietic and lymphoid tissues
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Fred Zheng, MD, PhDIncyte Corporation
- Intervention
- Parsaclisib(drug)
- Enrollment
- 126 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2024
Study locations (30)
- Arizona Oncology Associates - Biltmore Cancer Center, Phoenix, Arizona, United States
- Beverly Hills Cancer Center, Beverly Hills, California, United States
- Synergy Hematology and Oncology Medical Associates, Los Angeles, California, United States
- St. Joseph Heritage Healthcare, Santa Rosa, California, United States
- American Institute of Research Corporate Office, Whittier, California, United States
- Cancer Center of Central Connecticut, Southington, Connecticut, United States
- Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
- Asclepes Research Centers, Spring Hill, Florida, United States
- Clinical Trials of Swla Llc, Lake Charles, Louisiana, United States
- Saint Agnes Hospital, Baltimore, Maryland, United States
- Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan, United States
- Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
- Saint Luke'S Hospital, Kansas City, Missouri, United States
- Sarah Cannon Research Institute, Kansas City, Missouri, United States
- Clinical Research Alliance, Inc., New Hyde Park, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03126019 on ClinicalTrials.govOther trials for Tumor of hematopoietic and lymphoid tissues
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07249346Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationHannah Choe, MD
- RECRUITINGPHASE1NCT06904066Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07270770BY002 IIT Study in R/R Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07257419CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company
- RECRUITINGPHASE1, PHASE2NCT07471789Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala Therapeutics
- RECRUITINGNANCT07051525Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsITM Solucin GmbH
See all trials for Tumor of hematopoietic and lymphoid tissues →